In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
Combination of novel pathogenic variants in sarcomeric proteins genes and GLA gene in relatives with hypertrophic cardiomyopathy
Authors : E Sadauskiene (Vilnius,LT), I Eitaviciute (Vilnius,LT), L Venceviciene (Vilnius,LT), J Barysiene (Vilnius,LT), Z Petrulioniene (Vilnius,LT), K Vencevicius (Vilnius,LT)
E Sadauskiene1
,
I Eitaviciute2
,
L Venceviciene1
,
J Barysiene1
,
Z Petrulioniene1
,
K Vencevicius2
,
1Institutes of Biomedical Sciences and Clinical Medicine, Faculty of medicine, Vilnius University - Vilnius - Lithuania
,
2Vilnius University, Medicine faculty - Vilnius - Lithuania
,
Topic(s): Hypertrophic Cardiomyopathy
Introduction Hypertrophic cardiomyopathy (HCM) is a primary cardiac muscle disease defined by left ventricular hypertrophy (LVH), in the absence of abnormal loading conditions. Clinical presentation of the disease shows great variability, ranging from little or no cardiovascular symptoms to heart failure (HF) and sudden cardiac death (SCD). Screening of patients with HCM of unknown aetiology reveals a high prevalence (1-12%) of Fabry disease (FD). Purpose Our aim is to demonstrate a confusing case of 4 relatives with HCM phenotype, who were suspected having FD after genetic variant of unknown significance (GVUS) in a-galactosidase A (GLA) gene was identified in 2 of 3 alive patients. As the cause of HCM remains uncertain, it is recommended to perform a sequencing of sarcomere protein genes. Methods A GVUS in GLA gene c.937G>T (p.Asp313Tyr) was identified in 2 of 4 patients with HCM phenotype. Since clinical features and histological findings consistent with FD were absent, the cause of HCM was still uncertain after evaluation of patients’ medical history, physical, laboratory, instrumental examination and histological data, next generation sequencing of sarcomere proteins’ genes was performed to three relatives (I-1, II-3, and III-1). Coding sequences of the genes associated with HCM (ACTC1, ACTN2, BRAF, CAV3, CSRP3, GAA, GLA, HRAS, KRAS, MAP2K1, MAP2K2, MYBPC3, MYH6, MYH7, MYL2, MYL3, MYLK2, MYOZ2, NEXN, NRAS, PLN, PRKAG2, PTPN11, RAF1, SOS1, TCAP, TNNC1, TNNI3, TNNT2, and TPM1) were analysed. Results We report a case of four patients from one family with HCM phenotype, progressive HF and SCD of the proband‘s (I-1) older daughter (II-1). Since classical clinical features consistent with FD were absent, renal and endomyocardial biopsies were performed for proband and her daughter (II-3). Histological analysis of proband's renal tissue revealed minimal histological changes which could be consistent with FD. Histological examination of proband’s daughter’s myocardium showed no histological changes. Next generation sequencing of sarcomere proteins’ genes revealed two heterozygous pathological variants in all patients: PLN gene c.26_29dupGCTC (p.Ala11Leufs*10) and MYBPC3 gene c.3530_3531insG (p.Phe1177Leufs*31). Conclusion Data of the current case suggests that GLA gene variant c.937G>T p.(Asp313Tyr) is not necessarily associated with FD. Two novel heterozygous pathogenic variants in sarcomeric protein genes which have not been previously reported in the literature – PLN gene c.26_29dupGCTC p.(Ala11Leufs*10) and MYBPC3 gene c.3530_3531insG (p.Phe1177Leufs*31) – determine the development of HCM phenotype. Multiple mutations are related to an earlier presentation of HCM with more severe phenotype and higher risk of sudden cardiac death. Multiple variants in sarcomeric protein genes should be recommended as an additional biomarker in the assessment of SCD.